Commercial Analytics

RxDataSolutions (RxDS) helps transform the sales and account management strategies in response to evolving value drivers and customer dynamics. Our proprietary platform enables commercial data aggregation, integration, and analysis to simplify this process and makes decision making more effective by connecting multiple data sources relevant to the physicians and institutions. We combine evidence generation and robust data analytics to drive launch success across the product lifecycle. 

We provide tools to get an in-depth view of market characteristics and understand the opportunity. The advancement in precision medicine, including new and innovative therapies like biologics, RNA, gene therapy, and CAR-T combined with digital health initiatives are providing new opportunities to improve patient lives. The industry is shifting towards a “Patient Centric” commercial model.

• With patient being the real customer, these treatments also have a very complex patient journey life cycle including finding patients, matching with the HCP, delivering the treatment and ultimately assessing the commercial value of the drug based on effectiveness. 
• Performing analytics on claims related data (eg, IMS) and deriving insights during new product launch and comparing the commercial share of the market is a key aspect for drugs which meets the needs of larger population sets.
• For rare disease companies, there are even more significant challenges based on
  - Lower prevalence, lack of adequate knowledge about the disease course, and phenotype heterogeneity
  - Smaller number of patient population
  - More challenging to find and diagnose patients
  - Market sizing and targeting is more complex compared to the traditional diseases (eg, diabetes)